Wednesday, October 18, 2017
 
 
Company News: Page (1) of 1 - 10/10/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
 
(October 10, 2017)

NEW YORK, Oct. 10, 2017 /PRNewswire/ -- The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.


Read the full report: https://www.reportlinker.com/p03596607


? The global noncancer market is expected to grow from $1.3 billion in 2017 to $2.6 billion in 2022 at a CAGR of 15.2% for the period 2017-2022.
? The global cancer market is expected to grow from $229.3 million in 2017 to $1.9 billion in 2022 at a CAGR of 52.4% for the period 2017-2022.

Chapter 1: Introduction
Study Goals and Objectives
BCC Research's goal for this study is to provide an in-depth update study of the liquid biopsy diagnostics industry, an emerging industry with high market potential. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geography. The market sizes are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

Market segments that provide exceptional growth opportunities include cancer therapy guidance and monitoring and organ transplant surveillance.

The report provides a comprehensive discussion of liquid biopsy technologies, clinical applications, industry structure, liquid biopsy funding initiatives, global markets, patent status and companies. The report is designed to provide an in-depth analysis of the industry and markets and aid companies in their strategic planning efforts relating to life science tools and diagnostics.

Reasons for Doing This Study
Traditional biopsy methods are often invasive, uncomfortable and carry risks of side effects. Liquid biopsy addresses these issues because it is noninvasive and carries little, if any, side effect risks.

In the age of genomics and personalized medicine, it is critical for clinicians to have diagnostic tools that can be used on a regular basis to screen, monitor, conduct surveillance, guide treatment or otherwise give valuable genomic information about a disease. Liquid biopsy provides this capability and thus is of high interest to the medical community.

Liquid-biopsy-enabling technologies are coming to the forefront and provide significant market growth momentum to the industry. Downstream analysis technologies like next-generation sequencing and digital polymerase chain reaction (PCR) are progressing in capabilities, efficiency, and costs. Upstream technologies like microfluidics, cell-free deoxyribo nucleic acid (DNA) capture and isolation, cell capture, and DNA amplification are also making significant progress.

Liquid biopsy is also gaining significant traction with key opinion leaders, medical societies and insurance payors.

As a result, liquid biopsy is penetrating into attractive clinical applications, including average-risk noninvasive prenatal testing and cancer therapy guidance and monitoring.

Based on these trends, liquid biopsy markets are rapidly emerging and the need for industry and market characterization is great.

The outstanding growth potential for liquid biopsy diagnostics makes it particularly timely for preparing this updated report.

Scope of Report
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. It then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. Market driving forces are also discussed.

The structure of several important industry subsectors is reviewed, as well as major industry acquisitions and strategic alliances from January 2016 through July 2017. Industry subsectors analyzed include next- generation sequencing (NGS) instruments, droplet digital PCR, target enrichment and amplification, single-cell DNA polymerase, prenatal screening, liquid biopsy, direct to consumer, and clinical laboratory.

The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia-Pacific, Rest of World). Market data cover the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).
More than 165 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2016 through July 2017, including key alliance trends.

Information Sources
BCC Research performed both primary and secondary research for this report. Primary sources included industry companies and leading research institutions and secondary sources included company websites and industry, trade and government publications.

Methodology
Both primary and secondary sources were consulted for this report, and a study of the industry trends was performed. BCC Research examined each of the key enduser market segments that will be commercially important during the forecast period: cancer, transplant medicine and reproductive health.

Based on this analysis, the current and future applications of liquid biopsy products are evaluated in each of the major clinical market segments and historical sales revenues are given for 2015 and 2016, estimated revenues are given for 2017, and forecast revenues are given for 2022.

Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:

North America
? U.S.
? Mexico.
? Canada.

Europe
? Austria.
? Belgium.
? Czech Republic.
? Denmark.
? Estonia.
? France.
? Finland.
? Germany.
? Greece.
? Hungary.
? Iceland.
? Italy.
? Ireland.
? Luxembourg.
? Netherlands.
? Norway.
? Poland.
? Portugal.
? Romania.
? Spain.
? Sweden.
? Switzerland.
? Turkey.
? U.K.

Asia-Pacific
? Australia.
? China.
? Hong Kong.
? India.
? Japan.
? Malaysia.
? New Zealand.
? Philippines.
? Singapore.
? South Korea.

? Taiwan.
? Thailand.

Rest of World
? Argentina.
? Brazil.
? Chile.
? Israel.
? Kuwait.
? Russia.
? Saudi Arabia.
? South Africa.
? United Arab Emirates.

Liquid Biopsy Market, by Application
Cancer
Reproductive Health
Transplant Medicine

Liquid Biopsy Market, by Biomarker Type
Nucleic Acids
Cells
Extracellular Vesicles
Proteins

Liquid Biopsy Market, by Analysis Platform
Microarray
NGS
PCR
Proteomics
Other

Liquid Biopsy Market, by Analysis Purpose
Screening/Early Detection
Diagnosis
Therapy Guidance
Monitoring

Chapter 2: Summary and Highlights
Liquid biopsy is rapidly gaining traction as a supplement or alternative to doing a tissue biopsy for applications in reproductive health, cancer and transplant medicine. The liquid biopsy captures and analyzes biomarkers, mostly cell-free DNA, found in body fluids, most often in blood.

In the noninvasive prenatal testing market, liquid biopsy has achieved significant penetration in the high-risk pregnancy segment and is moving into the low-risk sector.

In cancer, liquid biopsy is gaining significant market traction. Two trends stand ou agnostic labeling strategy for cancer drugs is driving the use of liquid biopsy companion diagnostics. An example of the former trend is the agreement in June 2017 by the U.S. Department of Veterans Affairs to provide a liquid biopsy test, PlasmaSelect 64, to advanced cancer patients being treated at its facilities.

An example of the latter trend is the expanded approval in May 2017 by the U.S. Food and Drug Administration (FDA) of the checkpoint inhibitor drug Keytruda (Merck, pembrolizumab) for advanced cancer patients with microsatellite instability or mismatch repair deficiency. This approval highlighted a new paradigm in cancer care, where the patient is treated based on specific genomic defects rather than on the organ of origin. This will boost the market for molecular diagnostics that can detect these genomic markers and be used to guide treatment decisions associated with these drugs.

The global liquid biopsy market is estimated to be $1.5 billion in 2017 and is growing at a compound annual growth rate 24.2% to reach a forecast size of $4.5 billion by the year 2022.

The two main applications for liquid biopsy are cancer and noncancer (reproductive health and organ transplant diagnostics).

The global cancer market is estimated to be $229.3 million in 2017 and is growing at a compound annual growth rate of 52.4% to reach a forecast size of almost $1.9 billion by 2022.

Key growth sectors in the liquid biopsy cancer market include tests for lung cancer, pan-cancer tests that can detect cancer recurrence, and tests that can provide real-time assessment of disease progression or drug response. Liquid biopsy gives physicians a key tool for assessing whether a patient is taking the right drug in light of a wider choice of therapies coming onto the market.

The global noncancer market is estimated at nearly $1.3 billion in 2017 and is growing at a compound annual growth rate of 15.2% to reach a forecast size of $2.6 billion by 2022.

Driving this market has been the success of noninvasive prenatal testing (NIPT) for high-risk pregnancies.
Test providers are focusing on the low-risk sector as well as on test differentiation as strategies to maintain growth.

A third high-potential market sector for liquid biopsy is for organ transplantation diagnostics. In this market, there is a strong need for noninvasive diagnostics that can detect the early onset of organ rejection so that immunosuppression can be optimized.

Circulating cell-free DNA is fast emerging as the predominant biomarker for liquid biopsy for all market segments. This creates a market opportunity for companies who have or can develop proprietary technologies for improving the workflow for capturing, detecting and analyzing this biomarker type.

The liquid biopsy industry is dynamic and gaining substantial traction in its three main clinical market segments. This report provides a comprehensive overview and analysis of this industry, which is undergoing exceptional growth and promises to transform medical treatment and surveillance strategies.

Read the full report: https://www.reportlinker.com/p03596607

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

https://www.reportlinker.com


__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/liquid-biopsy-research-tools-services-and-diagnostics-global-markets-300534161.html

SOURCE Reportlinker


Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA, Medicine, Disease, healthcare, Pregnancy, Cancer, Surgery, Medication, Pregnancy, Science, Medical, Agricultural Science, Biology, Genetics, Cancer, Science,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines